ReachRxResearch
Home
Research
Sign Up
Remibrutinib versus teriflunomide in relapsing multiple sclerosis (REMODEL-1 and REMODEL-2): two randomised, phase 3 trials
Back to Research Hub
  1. Home
  2. Research Hub
  3. Remibrutinib versus teriflunomide in rel…

Remibrutinib versus teriflunomide in relapsing multiple sclerosis (REMODEL-1 and REMODEL-2): two randomised, phase 3 trials

The Lancet·October 23Open Access
Medicine, General & InternalPractice changingRelapsing Multiple SclerosisRandomized Controlled TrialBTK InhibitorAdultAubagioRemibrutinibTeriflunomide

Summary

View source

What was studied

Two identical phase 3 RCTs (REMODEL-1 and REMODEL-2) compared oral remibrutinib 100 mg twice daily versus teriflunomide 14 mg once daily in adults aged 18–55 with relapsing MS and recent disease activity, over up to 30 months of follow-up (n=2,007 total).

Key findings

Remibrutinib significantly reduced annualised relapse rate vs teriflunomide in both trials: ARR 0.073 vs 0.112 (rate ratio 0.648; p=0.018) in REMODEL-1 and 0.080 vs 0.116 (rate ratio 0.688; p=0.034) in REMODEL-2, representing roughly 31–35% relative reductions. Adverse events leading to discontinuation were less frequent with remibrutinib (3.1%) than teriflunomide (5.8%), and alopecia was notably less common (5.8% vs 13.5%).

Study limitations

Comparator was teriflunomide, a moderate-efficacy therapy, leaving remibrutinib's performance vs higher-efficacy agents unknown. Longer-term disability outcomes (e.g., confirmed disability progression) were not reported as primary endpoints. The trial population was capped at age 55 and required recent disease activity, limiting generalisability to older or lower-activity patients.

Clinical implications

Remibrutinib, an oral CNS-penetrant BTK inhibitor, reduced relapse rates by about one-third compared to teriflunomide with a favourable tolerability profile, including fewer discontinuations and less alopecia. Clinicians treating relapsing MS may consider it a promising oral option, though head-to-head data against high-efficacy therapies are still needed.

Caveats

  • Disability progression data were not reported as a primary outcome, so the long-term impact on irreversible disability accumulation remains unclear
  • The active comparator, teriflunomide, is a moderate-efficacy agent; superiority over it does not establish remibrutinib's place relative to high-efficacy MS therapies
  • Trial was industry-funded by Novartis, which should be considered when interpreting reported outcomes

Related Questions

Explore related topics

How does remibrutinib compare to high-efficacy therapies like natalizumab or ocrelizumab in relapsing MS?What is the role of BTK inhibitors in multiple sclerosis and how do they differ from existing oral disease-modifying therapies?What disability progression outcomes have been reported with BTK inhibitors in MS clinical trials?

Publication Details

Year
2026
Journal
The Lancet
Sample Size
n=2,007
Source
View article
Keep scrolling
More content below.
Up Next